International Journal of Advanced and Integrated Medical Sciences

Register      Login

VOLUME 2 , ISSUE 4 ( 2017 ) > List of Articles

ORIGINAL ARTICLE

A Cadaveric Study of Sacralization of Fifth Lumbar Vertebra

Shikky Garg

Keywords : Genes, Low back pain, Lumbar vertebra, Sacralization, Sacrum

Citation Information : Garg S. A Cadaveric Study of Sacralization of Fifth Lumbar Vertebra. Int J Adv Integ Med Sci 2017; 2 (4):190-192.

DOI: 10.5005/jp-journals-10050-10104

License: CC BY-SA 4.0

Published Online: 01-06-2018

Copyright Statement:  Copyright © 2017; The Author(s).


Abstract

Introduction In humans, sacrum consists of five fused sacral vertebrae. Anatomically, this fusion provides strength and stability to the pelvis and transmits the weight of the body to the pelvic girdle through the sacroiliac joints. Lumbosacral transitional vertebrae (LSTVs) are congenital anomalies of the lumbosacral region, which include sacralization of fifth lumbar vertebra and lumbarization of first sacral vertebra. Low back pain is quite a common ailment affecting about 80% of the population in their lifetime. Lumbosacral transitional vertebra is one of the causes of low backache. Objective (1) Prevalence of sacralization of fifth lumbar bone. (2) Prevalence of various types of fusion. Materials and methods In the present study, 100 cadaveric spinal cords were examined in the Department of Anatomy, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India. Results In the present study of 100 adult cadaveric human sacra, 61 were male and 39 were female. Out of 100 sacral bones, 17 showed sacralization of fifth lumbar vertebrae and remaining 83 were normal vertebra. Out of 17 sacralized bones, 15 bones showed bilateral sacralization and only 2 bones showed unilateral sacralization. Conclusion Being a cause of low backache, knowledge of sacralization is of great importance for not only the orthopedician but also for radiologist and physiotherapist. Correct knowledge of presence of LSTV may help in correct treatment with appropriate rehabilitation. How to cite this article Garg S. A Cadaveric Study of Sacralization of Fifth Lumbar Vertebra. Int J Adv Integ Med Sci 2017;2(4):190-192.


PDF Share
  1. Romanes, GJ. Cunningham's text book of anatomy. 10th ed. London: Oxford University Press; 1964. pp. 92-93.
  2. Bertolotti M. Contributto alla conoscenza dei vici di differenzarione regionale del rachide con special riguards all asimilazzione sacrale della v. Lombare. Radiol Med 1917;4:113-144.
  3. Dullerud R. Diagnostic imaging in lumbago and sciatica. Ugeskr Laeger 1999 Sep;161(38):5299-5303.
  4. Sadler TW. Langman's medical embryology. 11th ed. Philadelphia (PA): Wolters Kluwer/Lippincott Williams and Wilkins; 2010. p. 142.
  5. Singh R. Analytical view of the simultaneous occurrence of sacralisation and congenital anomalies. Eur J Anat 2012 Apr;16(2):127-130.
  6. Bustami F. The anatomical features and functional significance of lumbar transitional vertebra. Jordan Med J 1989;23:49-59.
  7. Dharati K, Nagar SK, Ojaswini M, Dipali T, Paras S, Sucheta P. A study of sacralisation of fifth lumbar vertebra in Gujarat. Natl J Med Res 2012 Apr-Jun;2(2):211-213.
  8. Brothewell, DR. Of mice and men. Epigenetic polymorphism in the skeleton. In: Caso A, et al. Homenaie a juan Comas en Su 65 Aniversaria. Vol. 2. Mexico: Editorial Libros de México; 1965. p. 9-21.
  9. MollerChristensen, Sandison AT. Usura orbitae (enbra orbitalia) in the collection of crania in the Anatomy department of university of Glasgow. Path Microbiol 1963;26:175-183.
  10. Roche AF. Aural exotoses in Australian aboriginal skulls. Ann Otol Rhinol Laryngol 1964 Mar;73:82-91.
  11. Dorsey GA. Wormian bones in artificially deformed Kwakiutl crania. Am Anthropol 1897 Jun;10(6):169-173.
  12. Chambellan, M. Etude Anatomique et Anthropologique sur les Os Wormiens. Thesis, Paris. [Cited by Dorsey, 1897]. 1883.
  13. Russel F, Studies in Cranial Variation, Am Nat 1900;34:737-747.
  14. Wood-Jones F. The non-metrical morphological characters of the skull as criteria for racial diagnosis. IV. J Anat 1933-1934 Oct;68(Pt 1):96-108.
  15. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001 Apr;54(4):447-453.
  16. Karabulut AB, Cakmak M, Kiran RT, Sahin I. Oxidative stress status, metabolic profile and cardiovascular risk factors in patients with polycystic ovary syndrome. Med Sci 2012 Jan;1(1):27-34.
  17. Dalton M, Cameron AJ, Zimmet PZ, Shaw JE, Jolley D, Dunstan DW, Welborn TA, AusDiab Steering Committee. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Intern Med 2003 Dec;254(6):555-563.
  18. Chan DC, Watts GF. LDL heterogeneity revisited: lesson for the metabolic syndrome from a new interpopulation study? Eur J Clin Invest 2004 Nov;34(11):719-722.
  19. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos P. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007 Sep;18(7):280-285.
  20. Brunzell JD, Davidson M, Furberg CD. Lipoprotein management in patients with cardio metabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008 Apr;51(4):1512-1524.
  21. Nordestgaard BG, Langsted A, Freiberg JJ. Nonfasting hyperlipidemia and cardiovascular disease. Curr Drug Targets 2009 Apr;10(4):54-61.
  22. Peters AL. Clinical relevance of non-HDL cholesterol in patients with diabetes. Clin Diabetes 2008 Jan;26(1):3-7.
  23. Vaughan N, James K, McDermott D, Griest S, Fausti S. A 5-year prospective study of diabetes and hearing loss in a veteran population. Otol Neurotol 2006 Jan;27(1):37-43.
  24. Tosi A, Misciali C, Piraccini B, Peluso AM, Bardazzi F. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf 1994 Apr;10(4):310-317.
  25. Bronner AK, Hood AF. Cutaneous complication of chemotherapeutic agents. J Am Acad Dermatol 1983 Nov;9(5):645-663.
  26. Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin North Am 1986 Jan;70(1):187-209.
  27. Boyle DM, Engelking C. Vesicant extravasation: myths and realities. Oncol Nurs Forum 1995 Jan-Feb;22(1):57-67.
  28. Malkinson, FD. Radiobiology of the skin. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, editors. Fitzpatrick's dermatology in general medicine. 5th edn. New York: McGraw-Hill; 1999. pp. 1514-1523.
  29. Goldschmidt H, Breneman JC, Bareneman DL. Ionizing radiation therapy in dermatology. J Am Acad Dermatol 1994 Feb;30(2 Pt 1):157-182.
  30. Narkiewicz K, van de Borne P, Montano N, Hering D, Kara T, Somers VK. Sympathetic neural outflow and chemoreflex sensitivity are related to spontaneous breathing rate in normal men. Hypertension 2006;47(1):51-55.
  31. Agte VV, Chiplonkar SA. Sudarshan kriya yoga for improving antioxidant status and reducing anxiety in adults. Altern Complement Ther 2008;14(2):96-100.
  32. Jacobs GD. Clinical applications of the relaxation response and mind-body interventions. J Altern Complement Med 2001;7(Suppl 1):S93-S101.
  33. Singh N, Telles S. Heart rate variability and state anxiety in hypertensives and diabetes after one week of yoga. J Indian Psychol 2009;27(1-2):13-20.
  34. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S; British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV. J Hum Hypertens 2004 Mar;18(3):139-185.
  35. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, Myers MG, McKay DW, Quinn RR, Hemmelgarn BR, et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011 Jul-Aug;27(4):415-433.e1-2.
  36. Wahlgren NG, MacMahon DG, De Keyser JF, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994 May;4(3):204-10.
  37. Kaste M, Fogelholm R, Erilä T, Palomäki H, Murros K, Rissanen A, Sarna S. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994 Jul;25(7):1348-1353.
  38. Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003 Jul;34(7):1699-1703.
  39. Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011 Feb;377(9767):741-750.
  40. Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, Jagger C. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol 2009 Jan;8(1):48-56.
  41. Robinson TG, Potter JF, Ford GA, Bulpitt CJ, Chernova J, Jagger C, James MA, Knight J, Markus HS, Mistri AK, et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol 2010 Aug;9(8):767-775.
  42. Jauch EC, Saver JL, Adams HP, Bruno A, Demaerschalk BM, Khatri P, McMullan PW, Qureshi AI, Rosenfield K, Scott PA, et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke 2013 Mar;44(3):870-947.
  43. Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, Lees KR, Toni D; SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis. Stroke 2009 Jul;40(7):2442-2449.
  44. Karachalios GN, Charalabopoulos A, Papalimneou V, Kiortsis D, Dimicco P, Kostoula OK, Charalabopoulos K. Withdrawal syndrome following cessation of antihypertensive drug therapy. Int J Clin Pract 2005 May;59(5):562-570.
  45. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 Sep;358(9287):1033-1041.
  46. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Stroke 2005 Jun;36(6):1218-1226.
  47. Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008 Sep;359(12):1225-1237.
  48. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2014 Jan:45(7):2160-2236.
  49. Robb AO, Mills NL, Din JN, Smith IB, Paterson F, Newby DE, Denison FC. Influence of the menstrual cycle, pregnancy, and preeclampsia on arterial stiffness. Hypertension 2009 Jun;53(6):952-958.
  50. Avni B, Frenkel G, Shahar L, Golik A, Sherman D, Dishy V. Aortic stiffness in normal and hypertensive pregnancy. Blood Press 2010 Feb;19(1):11-15.
  51. Khalil A, Akolekar R, Syngelaki A, Elkhouli M, Nicolaides KH. Maternal hemodynamics at 11–13 weeks’ gestation and risk of pre-eclampsia. Ultrasound Obstet Gynecol 2012 Jul;40(1):28-34.
  52. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992 Feb;304(6824):405-412.
  53. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar;359(9311):995-1003.
  54. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trials-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep;366(9489):895-906.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.